淋巴结比率对胃癌根治术后辅助治疗选择的影响
基于美国多中心数据库719例胃癌根治性切除患者,评估淋巴结比率对辅助化疗或放化疗生存获益的影响。淋巴结比率>0.25者可从放化疗中获益,而≤0.25者未见生存获益。
要点
- 淋巴结比率>0.25的胃癌患者可从辅助放化疗中获生存获益。
- 淋巴结比率≤0.25的患者未观察到辅助化疗或放化疗的生存获益。
- 淋巴结比率>0.25与更差的总生存独立相关(HR 2.3)。
核心结论
- 淋巴结比率可能有助于筛选可从辅助放化疗中获益的胃癌根治术后患者。
- 放化疗的生存获益仅见于淋巴结比率>0.25的患者。
研究设计与样本
- 多中心回顾性队列研究,纳入美国胃癌协作组数据库2000至2013年间719例接受根治性切除的胃腺癌患者。
- 排除转移或R2切缘患者。
主要发现
- 中位年龄65岁,男性占56.2%。
- 中位总生存40.9个月,5年总生存率40.3%。
- 淋巴结比率0、0.01-0.10、>0.10-0.25、>0.25的5年总生存率分别为54.1%、53.1%、49.1%、19.8%。
- 与更差总生存相关的因素包括食管胃结合部受累(HR 1.8)、T分期3-4(HR 2.1)、淋巴血管侵犯(HR 1.4)、淋巴结比率>0.25(HR 2.3),均P<.05。
- 辅助放化疗相比单纯手术(HR 0.40)或化疗(HR 0.45)与总生存改善相关,均P<.001。
关键数值与推荐
- 淋巴结比率>0.25者,放化疗对比单纯手术HR 0.34,对比化疗HR 0.45,均P<.001。
- 淋巴结比率≤0.25者,化疗或放化疗均无总生存获益(P>.05)。
临床怎么用
- 胃癌根治术后可依据淋巴结比率分层,淋巴结比率>0.25者优先考虑辅助放化疗。
- 淋巴结比率≤0.25者辅助化疗或放化疗的生存获益不明确,需个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of adjuvant chemotherapy and chemo-radiation therapy in the treatment of resectable gastric cancer remains varied. We sought to define the clinical impact of lymph node ratio on the relative benefit of adjuvant chemotherapy or chemo-radiation therapy among patients having undergone curative-intent resection for gastric cancer. METHODS: Using the multi-institutional US Gastric Cancer Collaborative database, 719 patients with gastric adenocarcinoma who underwent curative-intent resection between 2000 and 2013 were identified. Patients with metastasis or an R2 margin were excluded. The impact of lymph node ratio on overall survival among patients who received chemotherapy or chemo-radiation therapy was evaluated. RESULTS: Median patient age was 65 years, and the majority of patients were male (56.2%). The majority of patients underwent either subtotal (40.6%) or total gastrectomy (41.0%), with the remainder undergoing distal gastrectomy or wedge resection (18.4%). On pathology, median tumor size was 4 cm; most patients had a T3 (33.0%) or T4 (27.9%) lesion with lymph node metastasis (59.7%). Margin status was R0 in 92.5% of patients. A total of 325 (45.2%) patients underwent resection alone, 253 (35.2%) patients received 5-FU or capecitabine-based chemo-radiation therapy, whereas the remaining 141 (19.6%) received chemotherapy. Median overall survival was 40.9 months, and 5-year overall survival was 40.3%. According to lymph node ratio categories, 5-year overall survival for patients with a lymph node ratio of 0, 0.01-0.10, >0.10-0.25, >0.25 were 54.1%, 53.1 %, 49.1 % and 19.8 %, respectively. Factors associated with worse overall survival included involvement of the gastroesophageal junction (hazard ratio 1.8), T-stage (3-4: hazard ratio 2.1), lymphovascular invasion (hazard ratio 1.4), and lymph node ratio (>0.25: hazard ratio 2.3; all P < .05). In contrast, receipt of adjuvant chemo-radiation therapy was associated with an improved overall survival in the multivariable model (versus resection alone: hazard ratio 0.40; versus chemotherapy: hazard ratio 0.45, both P < .001). The benefit of chemo-radiation therapy for resected gastric cancer was noted only among patients with lymph node ratio >0.25 (versus resection alone: hazard ratio R 0.34; versus chemotherapy: hazard ratio 0.45, both P < .001). In contrast, there was no noted overall survival benefit of chemotherapy or chemo-radiation therapy among patients with lymph node ratio ≤0.25 (all P > .05). CONCLUSION: Adjuvant chemotherapy or chemo-radiation therapy was utilized in more than one-half of patients undergoing curative-intent resection for gastric cancer. Lymph node ratio may be a useful tool to select patients for adjuvant chemo-radiation therapy, because the benefit of chemo-radiation therapy was isolated to patients with greater degrees of lymphatic spread (ie, lymph node ratio >0.25).
引用
- Kim Y, Squires MH, Poultsides GA, et al. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery. 2017. PMID: 28578142. doi:10.1016/j.surg.2017.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。